17,261 trials
Squamous Cell Carcinoma
Primary: Correlate the Presence of Specific Fc RIIIa Polymorphisms With Progression-free Survival in Subjects Receiving Cetuximab and Lenalidomide for SCCHN. — 1.8 months
Adenocarcinoma of the Gastroesophageal Junction · Metastatic Gastric Cancer · Advanced Unresectable Gastric Cancer
Primary: The Proportion of Patients With Objective Response (Complete Response or Partial Response) — 0.409 Proportion of patients — p=0.0012
Preterm Birth · Low Birth Weight <2500 Grams · Verylow Birthweight <1500 Grams
Primary: Birthweight — 40; 26 participants
Sarcoma, Soft Tissue
Primary: Percentage of Patients Hospitalized in Each Arm. — 35; 26 percentage of patients hospitalized
Autism
Primary: Change From Screening/Baseline in Social Responsiveness Scale (SRS) at 4 Weeks, 10 Weeks, 18 Weeks and 22 Weeks — -7.79; -14.76; -1.38; -14.48 units on a scale
Healthy
Primary: Percentage of Participants With Seroconversion in rLP2086 Specific Serum Bactericidal Assay (SBA) Titer 1 Month After Dose 2 — 0.0; 33.3; 63.6; 83.3 percentage of…
Lung Cancer
Primary: Determination of the Feasibility of a Cognitive Behavioral Smoking Cessation Intervention. — 17; 32 participants
Fallopian Tube Cancer · Female Reproductive Cancer · Ovarian Carcinosarcoma
Primary: Objective Response Rate, Evaluated According to the RECIST Criteria — 0 participants
Multiple Myeloma
Primary: Percentage of Patients With an Objective Response — 31 percentage of patients
Steatohepatitis
Primary: Histological Response Defined by Change From Baseline in Standardized Scoring of Liver Biopsies — 18; 18; 20 participants — p=0.57
Multiple Myeloma
Primary: The Maximum Tolerated Dose (MTD) of Carfilzomib — 36 mg/m^2
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Outcome Correspondence to Imaging Results With Fluorine-18 Fluorocholine PET/CT — 100; 100; 100; 0 %PET-positive cases in a given PSA range
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or…
Non-Small Cell Lung Cancer
Primary: Percentage of Participants Achieving Progression-Free Survival (PFS) Without Disease Progression or Death at 6 Months — 56.5; 57.2 percentage of participants
Radiotherapy-induced Nausea and Vomiting (RINV)
Primary: Complete Control (no Signs of Emesis or Moderate to Severe Nausea and no Use of Rescue Medication) Rate From the Start of Radiotherapy Until 24 Hours After the Third…